These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 31389463)

  • 21. Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure.
    Baggio LL; Huang Q; Brown TJ; Drucker DJ
    Gastroenterology; 2004 Aug; 127(2):546-58. PubMed ID: 15300587
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differential effects of oxyntomodulin and GLP-1 on glucose metabolism.
    Du X; Kosinski JR; Lao J; Shen X; Petrov A; Chicchi GG; Eiermann GJ; Pocai A
    Am J Physiol Endocrinol Metab; 2012 Jul; 303(2):E265-71. PubMed ID: 22621866
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oxyntomodulin analog and exendin-4 derivative lower plasma glucose in cattle.
    ThanThan S; Asada Y; Saito T; Ochiiwa K; Zhao H; Naing SW; Kuwayama H
    Domest Anim Endocrinol; 2017 Apr; 59():30-36. PubMed ID: 27888738
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery of a novel GLP-1/GIP dual receptor agonist CY-5 as long-acting hypoglycemic, anti-obesity agent.
    Liu C; Li C; Cai X; Zou Y; Mo J; Chen B; Cai Y; Han T; Huang W; Qian H; Zhang W
    Bioorg Chem; 2021 Jan; 106():104492. PubMed ID: 33268008
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Native Oxyntomodulin Has Significant Glucoregulatory Effects Independent of Weight Loss in Obese Humans With and Without Type 2 Diabetes.
    Shankar SS; Shankar RR; Mixson LA; Miller DL; Pramanik B; O'Dowd AK; Williams DM; Frederick CB; Beals CR; Stoch SA; Steinberg HO; Kelley DE
    Diabetes; 2018 Jun; 67(6):1105-1112. PubMed ID: 29545266
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice.
    Pocai A; Carrington PE; Adams JR; Wright M; Eiermann G; Zhu L; Du X; Petrov A; Lassman ME; Jiang G; Liu F; Miller C; Tota LM; Zhou G; Zhang X; Sountis MM; Santoprete A; Capito' E; Chicchi GG; Thornberry N; Bianchi E; Pessi A; Marsh DJ; SinhaRoy R
    Diabetes; 2009 Oct; 58(10):2258-66. PubMed ID: 19602537
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Stapled, Long-Acting Xenopus GLP-1-Based Dual GLP-1/Glucagon Receptor Agonists with Potent Therapeutic Efficacy for Metabolic Disease.
    Han C; Sun Y; Yang Q; Zhou F; Chen X; Wu L; Sun L; Han J
    Mol Pharm; 2021 Aug; 18(8):2906-2923. PubMed ID: 34240881
    [TBL] [Abstract][Full Text] [Related]  

  • 28. DPP-IV-resistant, long-acting oxyntomodulin derivatives.
    Santoprete A; Capitò E; Carrington PE; Pocai A; Finotto M; Langella A; Ingallinella P; Zytko K; Bufali S; Cianetti S; Veneziano M; Bonelli F; Zhu L; Monteagudo E; Marsh DJ; Sinharoy R; Bianchi E; Pessi A
    J Pept Sci; 2011 Apr; 17(4):270-80. PubMed ID: 21294225
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A novel thrombin-based triagonist with diabetes-protective and weight-lowering potential.
    Zhang J; Zhang Z; Ma C; Zeng L; Zhang Y; Wang P; Xu L
    Life Sci; 2020 Sep; 256():117853. PubMed ID: 32470452
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Partial agonism improves the anti-hyperglycaemic efficacy of an oxyntomodulin-derived GLP-1R/GCGR co-agonist.
    Pickford P; Lucey M; Rujan RM; McGlone ER; Bitsi S; Ashford FB; Corrêa IR; Hodson DJ; Tomas A; Deganutti G; Reynolds CA; Owen BM; Tan TM; Minnion J; Jones B; Bloom SR
    Mol Metab; 2021 Sep; 51():101242. PubMed ID: 33933675
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel coumarin modified GLP-1 derivatives with enhanced plasma stability and prolonged in vivo glucose-lowering ability.
    Han J; Sun L; Huang X; Li Z; Zhang C; Qian H; Huang W
    Br J Pharmacol; 2014 Dec; 171(23):5252-64. PubMed ID: 25039358
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Emerging roles of oxyntomodulin-based glucagon-like peptide-1/glucagon co-agonist analogs in diabetes and obesity.
    Zhihong Y; Chen W; Qianqian Z; Lidan S; Qiang Z; Jing H; Wenxi W; Bhawal R
    Peptides; 2023 Apr; 162():170955. PubMed ID: 36669563
    [TBL] [Abstract][Full Text] [Related]  

  • 33. DR10601, a novel recombinant long-acting dual glucagon-like peptide-1 and glucagon receptor agonist for the treatment of obesity and type 2 diabetes mellitus.
    Wang W; Wen X; Duan W; Wang X; Chen Y; Dong J; Yang Z; Fang J; Zhou Z; Yao G; Fang Y; Huang Y
    J Endocrinol Invest; 2020 May; 43(5):653-662. PubMed ID: 31786794
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sustained treatment with a stable long-acting oxyntomodulin analogue improves metabolic control and islet morphology in an experimental model of type 1 diabetes.
    Irwin N; Pathak V; Pathak NM; Gault VA; Flatt PR
    Diabetes Obes Metab; 2015 Sep; 17(9):887-95. PubMed ID: 26095087
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Unraveling oxyntomodulin, GLP1's enigmatic brother.
    Pocai A
    J Endocrinol; 2012 Dec; 215(3):335-46. PubMed ID: 23019069
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rational design of dimeric lipidated Xenopus glucagon-like peptide 1 analogues as long-acting antihyperglycaemic agents.
    Han J; Huang Y; Chen X; Zhou F; Fei Y; Fu J
    Eur J Med Chem; 2018 Sep; 157():177-187. PubMed ID: 30096651
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A GLP-1/glucagon (GCG)/CCK
    Zhao S; Yan Z; Du Y; Li Z; Tang C; Jing L; Sun L; Yang Q; Tang X; Yuan Y; Han J; Jiang N
    Br J Pharmacol; 2022 Sep; 179(17):4360-4377. PubMed ID: 35484823
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Investigation of structure-activity relationships of Oxyntomodulin (Oxm) using Oxm analogs.
    Druce MR; Minnion JS; Field BC; Patel SR; Shillito JC; Tilby M; Beale KE; Murphy KG; Ghatei MA; Bloom SR
    Endocrinology; 2009 Apr; 150(4):1712-22. PubMed ID: 19074579
    [TBL] [Abstract][Full Text] [Related]  

  • 39. BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy.
    Zimmermann T; Thomas L; Baader-Pagler T; Haebel P; Simon E; Reindl W; Bajrami B; Rist W; Uphues I; Drucker DJ; Klein H; Santhanam R; Hamprecht D; Neubauer H; Augustin R
    Mol Metab; 2022 Dec; 66():101633. PubMed ID: 36356832
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A novel GIP analogue, ZP4165, enhances glucagon-like peptide-1-induced body weight loss and improves glycaemic control in rodents.
    Nørregaard PK; Deryabina MA; Tofteng Shelton P; Fog JU; Daugaard JR; Eriksson PO; Larsen LF; Jessen L
    Diabetes Obes Metab; 2018 Jan; 20(1):60-68. PubMed ID: 28598027
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.